The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats
| Autor: | Sophie R. Cohen, Michelle L. Terry, Michael Coyle, Emily Wheelis, Ashley Centner, Samantha Smith, John Glinski, Natalie Lipari, Carla Budrow, Fredric P. Manfredsson, Christopher Bishop |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Pharmacology
Dyskinesia Drug-Induced Serotonin Vilazodone Hydrochloride Clinical Biochemistry Parkinson Disease Toxicology Biochemistry Rats Antiparkinson Agents Levodopa Rats Sprague-Dawley Disease Models Animal Behavioral Neuroscience Amantadine Animals Humans Oxidopamine Excitatory Amino Acid Antagonists Biological Psychiatry |
| Zdroj: | Pharmacology Biochemistry and Behavior. 217:173393 |
| ISSN: | 0091-3057 |
| Popis: | Parkinson's disease (PD) is a progressive, neurodegenerative movement disorder caused by loss of nigrostriatal dopamine (DA) neurons. DA replacement therapy using L-3,4-dihydroxyphenylalanine (l-DOPA) improves motor function but often results in l-DOPA-induced dyskinesia (LID) typified by abnormal involuntary movements (AIMs). In states of DA depletion, striatal serotonin (5-HT) hyperinnervation and glutamate overactivity are implicated in LID. To target these co-mechanisms, this study investigated the potential anti-dyskinetic effects of FDA-approved Vilazodone (VZD), a 5-HT transport blocker and partial 5-HT |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect